NCT05465980 is a clinical trial in Stroke, Acute, sponsored by Shenzhen Second People's Hospital.

Who is sponsoring NCT05465980?

NCT05465980 is sponsored by Shenzhen Second People's Hospital.

What condition does NCT05465980 study?

NCT05465980 studies Stroke, Acute.

Is NCT05465980 still recruiting?

NCT05465980 is currently status unknown. Last updated 20 July 2022.

Last reviewed 2022-07-20 · How we verify

NCT05465980

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Development and Validation of the Prediction Model for Cognitive Impairment

Status unknown Last updated 20 July 2022

What this trial tests

trial in Stroke, Acute in 496 participants. Status unknown.

Timeline

1 September 2022

Primary endpoint
31 December 2023

30 September 2024

Quick facts

Lead sponsor	Shenzhen Second People's Hospital
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	496
Start date	1 September 2022
Primary completion	31 December 2023
Estimated completion	30 September 2024

Conditions studied

Stroke, Acute — all drugs for Stroke, Acute →

Sponsor

Shenzhen Second People's Hospital

Who can join

60 and older, any sex, with Stroke, Acute. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

According to the "Chinese Stroke Report" released in 2020, the incidence of stroke in China is 1114.8/100,000, acute ischemic stroke (AIS) accounts for 70% to 80% of the total number of stroke population, and elderly stroke patients are up to 2/3. About 1/3 of stroke patients would experience post-stroke cognitive impairment (PSCI), which seriously affected patients' quality of life and survival time, and increases disease and economic burden. Therefore, early identification, assessment, prevention and intervention of PSCI, and improvement of patients' quality of life and prognosis have become the focus of clinical research. This is a prospective cohort study. We intend to: (1) continuously collect elderly AIS patients who will be admitted to the Department of Neurology, The Department of Rehabilitation and the Department of Gerontology of Shenzhen Second People's Hospital from 2022 year to 2024 year; (2) collect baseline and follow-up data, and build a prediction model for cognitive impairment in elderly AIS patients; (3) internal validation using Bootstrap model; (4) collect the data of the elderly AIS patients who will be admitted to Shenzhen Longhua District People's Hospital andShenzhen Longgang Central Hospital, and conduct external validation; (5) evaluate the predictive efficacy of the model.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Nonlinear relationship between triglycerides and cognitive function after acute ischemic stroke among older adults.
Cao S, Teng L, Gao M, Hu S, et al · · 2024 · cited 3× · PMID 38524625 · DOI 10.1016/j.heliyon.2024.e27943

Verify or expand the search:

Other recruiting trials for Stroke, Acute

Currently open trials in the same condition.

NCT06825897 — Delay AvoIding Primary Evaluation for ThRombectomy of Acute StrokE Patients With Large Vessel OCclusion in the Angiograp · NA · recruiting
NCT06658197 — Efficacy and Safety of Tenecteplase Bridging Mechanical Thrombectomy for Acute Large Vessel Occlusion Stroke · Phase 3 · recruiting
NCT07253870 — Comperative Effects of Transcutaneous Auricular and Cervical Vagus Nerve Stimulation in Subacute Stroke Patients · NA · recruiting
NCT06941753 — Off-script Diagnosis & Differential Diagnosis (D&D) Training and Residents' Stroke Knowledge · NA · recruiting
NCT06123650 — Post Stroke Dysphagia: Effect of Adding rTMS to Conventional Therapy on the Prevalence of Pneumonia. · NA · recruiting

Other Shenzhen Second People's Hospital trials

Trials by the same sponsor.

NCT06542016 — An Evaluation of the KCCQ Score in Predicting Cardiovascular Risk in Dialysis Patients · recruiting
NCT05540808 — The Value of Full-targeted Pathogen Capture Metagenomics Next Generation Sequencing in Etiological Diagnosis of Sepsis · unknown
NCT05603975 — Analgesic Effect of Esketamine in DCSB in Adultscontrolled Study · NA · unknown
NCT05452759 — Research of Spiral Exhalation Device Oxygen Therapy to Improve the Treatment Effect of Patients With Severe Pneumonia · NA · unknown
NCT05311943 — Treatment With Olverembatinib in CML-CP Patients Who Failed to at Least Two Previously Administered Second-generation TK · Phase 3 · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05465980 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shenzhen Second People's Hospital
Last refreshed: 20 July 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05465980.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing